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Summary
The association of idiopathic venous thrombosis with occult cancer is generally recognized. However, it has not been fully 
appreciated that thrombin generated during thrombosis can augment the malignant phenotype. Thrombin activates tumor cell 
adhesion to platelets, endothelial cells, and subendothelial matrix proteins; enhances tumor cell growth; increases tumor cell 
seeding and spontaneous metastasis; and stimulates tumor cell angiogenesis. These mechanisms are reviewed. Evidence is 
also presented to support the hypothesis that thrombin serves to preserve dormant tumor cells in individuals, preventing host 
eradication. It is proposed that tumor malignancy may be regulated by a procoagulant/anticoagulant axis.Introduction
The association of venous thrombosis and cancer has been recog-
nized for 140 years, and its first description is attributed to Armand 
Trousseau (Prins and Otten, 2004). The association of thrombosis 
and cancer has a prevalence rate of 10%–20% (Prins and Otten, 
2004). Of particular interest is the association of occult cancer with 
venous thromboembolism (VTE) in individuals aged 40 years and 
older of 4%–10% (Prins and Otten, 2004). Most tumor cells have 
constitutively active tissue factor on their surface capable of gener-
ating thrombin in plasma by combining with factor VIIa to activate 
factor IX to IXa and X to Xa on the activated platelet surface, result-
ing in the conversion of prothrombin to thrombin. Thus, malignancy 
initiates a “vicious cycle” in which greater tumor burden supplies 
greater thrombin and platelet-tumor interaction.
The purpose of this review is to provide evidence that (1) 
thrombin (thrombosis) contributes to a more malignant pheno-
type by activating platelet-tumor aggregation, tumor adhesion to 
subendothelial matrix, tumor growth and metastasis, and tumor-
associated angiogenesis; and (2) thrombin serves to preserve 
and/or activate dormant tumor cells residing in the host.
Role of platelets in experimental pulmonary metastasis
The requirement of platelets for experimental pulmonary metas-
tasis (induced by tail vein injection of tumor cells) and the abil-
ity of tumor cells to aggregate platelets was first recognized by 
Gasic and coworkers (Gasic et al., 1968). Numerous studies have 
demonstrated a role for platelets in the hematogenous dissemina-
tion of animal tumors. Many tumor cells require platelets for the 
development of metastasis (Camerer et al., 2004; Gasic et al., 
1973; Pearlstein et al., 1980); ultrastructural studies have dem-
onstrated arrested tumor emboli surrounded by platelets (Jones 
et al., 1971); several tumor cell lines induce thrombocytopenia in 
vivo (Gasic et al., 1973) and aggregate platelets in vitro (Gasic 
et al., 1973; Pearlstein et al., 1980); a correlation exists between 
the ability of some tumor cells to aggregate platelets in vitro and 
their requirement for experimental pulmonary metastasis in vivo 
(Gasic et al., 1973; Pearlstein et al., 1980).
The rationale for the platelet requirement in tumor metastasis 
can be explained by thrombin-activated platelets or tumor cells 
interacting with each other to form platelet-tumor emboli, and in 
so doing prolonging tumor survival in the circulation (Jones et al., 
cancer cell 10, November 2006 © 2006 elsevier iNc. 1971). For example, it has been shown that under basal conditions 
>98% of labeled tumor cells injected intravenously into mice dis-
appear within 24 hr (Fidler, 1970). Sequestration of tumor cells by 
platelets protects tumor cells from immunologic host surveillance 
by impeding natural killer cell-mediated elimination of tumor cells 
(Nieswandt et al., 1999). Platelets also secrete tumor cell growth 
and angiogenesis factors, such as platelet-derived growth factor 
(PDGF) (Kepner and Lipton, 1981), vascular endothelial growth 
factor (VEGF) (Mohle et al., 1997), and Angiopoietin-1(ANG-1) 
(Li et al., 2001). Platelet-derived lysophosphatidic acid (LPA) 
promotes tumor cell proliferation by binding the LPA1 receptor 
on breast (MDA-BO2) and ovarian (CHO) cancer cells. LPA also 
contributes to bone metastasis by stimulating the release of the 
bone osteoclast resorption stimulators interleukin IL-8 and IL-6 
(Boucharaba et al., 2004).
Platelet-tumor aggregation
At least two separate mechanisms of tumor-induced platelet 
aggregation have been identified (Lerner et al., 1983): (1) require-
ment for serum complement activation, a stable plasma cofactor 
other than fibrinogen, divalent cation, and the sialo-lipo-protein 
vesicular component of the tumor membrane (seen in murine 
SV40 transformed 3T3 fibroblasts and possibly a rat renal sar-
coma, PW20); (2) requirement for the generation of thrombin 
and a phospholipid component of the tumor plasma membrane 
(seen in the human colon carcinomas LoVo and HCT8 and an 
anaplastic murine cell line, HUT-20).
Inhibition of experimental tumor metastasis with anti-platelet-
aggregating agents has been controversial because the specific 
anti-platelet-aggregating agents, aspirin and ticlopidine, as well 
as prostaglandin I2, were unsuccessful (Karpatkin et al., 1984, 
1988). These disappointing results prompted a reevaluation of 
Gasic’s original observation, that platelets were necessary for 
metastasis. It was confirmed employing three different tumor cell 
lines (CT26, Lewis lung, B16 amelanotic melanoma). The new 
experiments demonstrated that the experimental platelet require-
ment was early (within the first 6 hr after injection of anti-plate-
let Ab) and that human platelets could reconstitute metastasis 
in mice initially protected by the induction of thrombocytopenia 
(Pearlstein et al., 1984). Focus was therefore directed toward 
adhesion, which is not inhibited by these agents.355
	 r e v i e wPlatelet-tumor adhesion
Early studies designed to measure the adhesion of tumor cells 
to platelets under static conditions revealed the requirement of 
platelet glycoprotein (GP) IIb/IIIa (integrin αIIbβ3), fibronectin, 
VWF, and the RGDS domain of the adhesive proteins for adhe-
sion. Experimental murine tumor metastasis with CT26, B16a, 
and T241 Lewis bladder cancer is blocked 45%–65% in vivo with 
an anti-VWF antibody (without inducing thrombocytopenia), and a 
monoclonal antibody against platelet GPIIb-IIIa blocks the platelet 
reconstitution effect in mice protected from pulmonary metasta-
sis with thrombocytopenia (Karpatkin et al., 1988). Soluble fibrin 
monomer also augments platelet-tumor cell adherence in vitro 
and in vivo and also requires platelet GPIIb-IIIa, as well as tumor 
ICAM-1 (Biggerstaff et al., 1999).
A recent study employing human colon carcinomas LS174HT 
and COLO205 has extended these observations for adhesion 
of tumor cells to platelets under dynamic flow conditions. A two 
phase sequential process for tumor adhesion to platelets under 
flow was demonstrated: platelet P-selectin mediates tumor cell 
tethering and rolling followed by stable adhesion initiated by 
GPIIb-IIIa and VWF, via an RGD-dependent mechanism (McCarty 
et al., 2000). Other recent studies have demonstrated the pres-
ence of the P-selectin receptors PSGL-1 (P-selectin glycopro-
tein ligand-1) and CD24 (GPI-linked surface mucin) in KS breast 
cancer cells (Aigner et al., 1998), the presence of distinct ligands 
for selectins on colon carcinoma mucin-type glycoproteins, and 
attenuation of tumor growth and metastasis in P-selectin-deficient 
mice in association with absence of in vivo platelet-tumor aggre-
gates (Kim et al., 1998).
The role of a required “GPIIb-IIIa-like” integrin on either the 
platelet, tumor cell, or other structure is supported by additional 
data. In experimental pulmonary metastases, the pentapeptide 
GRGDS blocks B16F10 melanoma metastases by 97% without 
impairing cellular tumorigenicity. This is due to inhibition of reten-
tion of tumor cells in the vasculature. Five times more cells are 
retained in control mice at 7 hr. This difference increases with time 
(Humphries et al., 1986). Similar results were noted in a second 
report in which platelets appeared not to be responsible, i.e., 
thrombocytopenia did not inhibit the RGDS effect (Humphries 
et al., 1988), suggesting that tumor cells may bind via an RGDS 
mechanism to structures other than platelets. The disintegrin 
Albolabrin, an RGD-containing peptide, inhibits attachment of 
B16F10 mouse melanoma to fibronectin or laminin when immo-
bilized on plastic in vitro and inhibits experimental pulmonary 
metastasis by 90% in vivo (Soszka et al., 1991).
It is likely that other adhesive ligands such as laminin 
(Terranova et al., 1984), vitronectin (Cheresh et al., 1989), type 
IV collagen (Kramer and Marks, 1989), and thrombospondin 
(Roberts et al., 1987), as well as other integrin receptors (Soszka 
et al., 1991), α3β1 (Klepfish et al., 1993), α5β1 (Klepfish et al., 
1993), and αvβ3 (Cheresh et al., 1989) are also involved in tumor 
adhesion (Roberts et al., 1987; Tuszynski et al., 1987), platelet-
tumor interaction (Roberts et al., 1987; Tuszynski et al., 1987), 
and metastases (Iwamoto et al., 1987; Tuszynski et al., 1987).
Thrombin induces platelet-tumor adhesion and experimen-
tal pulmonary metastasis
Thrombin both activates and enhances exposure of GPIIb-IIIa 
on the platelet membrane surface, as well as tumor surface (see 
below). Thrombin also induces the release of platelet fibronectin 
and VWF onto the platelet surface, suggesting bridging between 356 platelets and tumor cells via fibronectin and VWF. Thrombin acti-
vates tumor-platelet adhesion in vitro and metastasis in vivo. 
Thrombin treatment of platelets enhances tumor adhesion 2- to 
4-fold in six tumor cell lines (HM54 hamster melanoma; human 
HCT8 colon cancer and SK-Mel-28 melanoma; and murine B16a 
melanoma, KLN205 squamous cell, and CT26 colon cancer) 
(Nierodzik et al., 1991).
Importantly, in vivo experiments with thrombin substantiate 
these in vitro observations. When 0.2–0.5 units of thrombin are 
injected together with tumor cells intravenously (a dose titered 
not to reduce the platelet count), pulmonary metastases increase 
4- to 413-fold with two different syngeneic tumor cell lines (CT26 
and B16a) (Nierodzik et al., 1991).
Thrombin-activated tumor cells enhance adhesion to naive 
platelets and endothelial cells
A direct effect of thrombin on tumor cells was next described 
in which a 3-fold increased adhesion of thrombin-treated tumor 
cells to platelets was noted. When thrombin-treated platelets 
and thrombin-treated tumor cells are added together, no addi-
tive effect is obtained (Nierodzik et al., 1991), suggesting that 
thrombin-treated tumor cells and thrombin-treated platelets are 
operating through the same mechanism. Five of seven tumor 
cell lines from three different species are activated by thrombin 
(B16a, HCT-8, Lewis lung, HM29, SK-Mel-28) to adhere to plate-
lets. The thrombin effect is maximum after 1 hr of incubation and 
is not inhibited by the protein synthesis inhibitor cycloheximide 
or the thrombin competitive inhibitor DAPA [dansyl-arginine N-(3-
ethyl-1, 5 pentanediyl) amide] added after thrombin activation, 
indicating that thrombin induces a secondary event (Nierodzik et 
al., 1991). Thrombin-activated tumor cells (SKMel-28 and HM29) 
also enhance their adhesion to bovine aortic and capillary endo-
thelial cells 2.1- to 2.3-fold under static conditions (Klepfish et al., 
1993). Similar observations occur under flow conditions in which 
thrombin increases the adhesion of human melanoma 397 cells 
to endothelial cells 2.2-fold and under conditions in which adhe-
sion is blocked by antibodies to GPIIb-IIIa as well as P-selectin 
(Dardik et al., 1998); 51Cr-labeled tumor cells (HELA or HT29) 
have greatly increased adhesion to endothelial cells in culture in 
the presence of both platelets and thrombin compared to platelets 
or thrombin alone (Helland et al., 1997).
Thrombin also serves to disrupt endothelial cell junctions 
supported by vascular endothelial cadherin (VE cadherin) and 
β-catenin (Konstantoulaki et al., 2003). Ab against VE cadherin 
inhibits neovasculature and tumor growth (Liao et al., 2000).
Of particular interest is the observation that the thrombin-
treated melanoma tumor cells studied also have a “GPIIb-IIIa-like” 
receptor on their surface (inhibited by anti-GPIIb-IIIa and RGDS) 
(Boukerche et al., 1989; McGregor et al., 1989; Nierodzik et al., 
1992). M3Dau melanoma cells, which react with platelets, bind a 
GPIIb-IIIa-specific monoclonal antibody, synthesize “GPIIb-IIIa-
like” glycoproteins, and do not react with Glanzmann thrombas-
thenia platelets (congenital absence of GPIIb-IIIa) (Boukerche 
et al., 1989). When preincubated with anti-GPIIb-IIIa antibody, 
M3Dau tumor cell growth is dramatically inhibited following sub-
cutaneous implantation into nude mice (Boukerche et al., 1989). 
Sixteen of twenty-one human malignant melanoma frozen biop-
sies bind to an anti-GPIIb-IIIa antibody, whereas negative results 
are obtained with 15 benign human melanocyte specimens and 
73 of 75 other human carcinomas (McGregor et al., 1989). GPIIb-
IIIa has been reported in 17 tumor cell lines of different histologi-cancer cell November 2006
	 r e v i e wFigure 1. summary figure: events occurring fol-
lowing tumor intravasation, tumor-platelet-endo-
thelial cell binding and platelet-tumor thrombus 
formation, tumor-platelet embolization, angio-
genesis, and extravasation
(1) migration of tumor cells into the vasculature is 
stimulated by thrombin, which is induced by tissue 
factor on the surface of most tumor cells. other 
factors stimulating migration also play a role. (2) 
Thrombin and other tumor-secreted agents acti-
vate endothelial cells, so that they now have P-
selectin on their surface. P-selectin binds weakly 
to tumor cells containing the P-selectin ligand 
receptor. Weakly activated platelets also bind 
tumor cells via P-selectin on their surface. This 
induces weak tethering of tumor to endothelium 
and platelets. (3) A tighter combination of plate-
lets and tumor cells develops, which produces 
thrombin at a more rapid rate, since platelets 
provide a catalytic surface for thrombin genera-
tion from coagulant proteins. This leads to a firm 
bond between platelets and tumor cells, medi-
ated by platelet integrin iib-iiia binding to tumor 
integrins via vWF, fibronectin, and other rGDs 
ligands. This also leads to angiogenesis via throm-
bin-stimulated synthesis and secretion of veGF 
and Gro-α from tumor cells—as well as release 
of PDGF, veGF, and ANG-1 from platelets, and 
increased ANG-2 and KDr in endothelial cells. 
Activated platelets and tumor cells secrete proangiogenic growth factors, which dominate over antiangiogenic factors. (4) Platelet-tumor aggregates pro-
tect tumor cells from NK cells and embolize downstream, leading to ischemic and endothelial cell denudation. Tumor cells and platelets bind more avidly to 
subendothelial basement membrane and matrix. (5) Tumor emboli lead to tumor extravasation into the parenchyma and neoangiogenesis.cal origin: skin, blood, lung, liver, kidney, cervix, colon, bladder, 
breast, and prostate.
Genetic confirmation of the role of circulating platelets, plate-
let-tumor cell activation, and fibrinogen in experimental pulmonary 
metastasis has recently been studied in a B16 melanoma model 
in NF-E2−/− knockout mice with virtually no circulating platelets, 
and in PAR-4−/− knockout mice (the major thrombin receptor in 
mice) with platelets that fail to respond to thrombin. Similar results 
were noted with fibrinogen Fib−/− knockout mice, indicating that 
fibrinogen is also necessary for metastasis (Camerer et al., 2004). 
Marked reduction in experimental pulmonary metastasis is seen 
in all three groups (6%, 14%, and 24% of wild-type, respectively). 
Of considerable interest are the recent observations obtained 
with Gαq−/− platelet knockout mice, a critical G protein required 
for platelet activation. Experimental and spontaneous pulmo-
nary metastasis obtained with syngeneic Lewis lung as well as 
B16-BL6 tumor cells are decreased by ?100-fold and ?60-fold, 
respectively (Palumbo et al., 2005). However, Gαq−/− platelets 
have no effect on subcutaneous tumor growth in vivo.
Thrombin-activated PAR-1 on tumor cells enhances experi-
mental pulmonary metastasis
Important in vivo experiments with thrombin-activated tumor cells 
(CT26, B16F1, B16F10) revealed experimental pulmonary metas-
tases that were enhanced 10- to 156-fold (Nierodzik et al., 1992). 
This demonstrated for the first time a cause and effect relationship 
between in vivo thrombin generation and cancer.
Thrombin activates its G-coupled seven transmembrane 
protease-activated receptor (PAR-1) by cleaving the receptor’s 
N-terminal end. The tethered end folds back on the second 
extracellular loop and activates the cell. Similar activation can be 
obtained with the six N-terminal amino acids of the new tethered 
end, SFLLRN. PAR-1 is present on seven of seven tumor cells 
examined by immunoblot and four additional cell lines examined 
by RT-PCR. Seven of eleven lines respond to the PAR-1 thrombin cancer cell November 2006 receptor activation peptide (TRAP), by a 2- to 3-fold enhanced 
adhesion to platelets (Nierodzik et al., 1996). Two TRAP-treated 
murine cell lines, B16F10 and CT26, enhance their experimental 
pulmonary metastasis 17- to 320-fold, despite having no effect 
on enhanced adhesion to platelets, suggesting that thrombin 
stimulates other tumor growth/metastasis-promoting properties, 
as well as adhesion. Activation of PAR-1 stimulates chemoki-
nesis of melanoma and prostate tumor cells (Shi et al., 2004). 
Overexpression of PAR-1 in B16 malignant melanoma cells leads 
to a 5-fold enhancement of experimental pulmonary metasta-
sis (Nierodzik et al., 1998). A precedent for thrombin-induced 
enhanced oncogenesis is supported by the observations that 
thrombin can act as a mitogenic agent for mesenchymal tissue: 
fibroblasts, endothelial cells, and smooth muscle cells (Carney 
et al., 1984; Chen and Buchanan, 1975; Gospodarowicz et al., 
1978). Indeed, PAR-1 has been recognized as a possible potent 
oncogene in a cDNA expression library screen for genes that 
induce focus-forming activity, and transformation of NIH 3T3 cells 
in vitro. This was associated with Rho-mediated signaling path-
ways, loss of anchorage independence, and serum-dependent 
growth (Martin et al., 2001).
It is likely that thrombin could be acting as a growth-stimula-
tory signal through its activation of PAR-1, leading to downstream 
mitogenic signaling events. It is unlikely that thrombin induces a 
malignant phenotype in primary cells, but more likely that persis-
tent thrombin signaling acts as an additional tumorigenic event 
in malignant cells or cells programmed to become malignant, 
through combinations of various events (Hanahan and Weinberg, 
2000). Thrombin also contributes to the malignant phenotype by 
the induction of angiogenesis following upregulation of vascular 
growth factors released from the tumor as well as platelets, which 
stimulate endothelial cell tumor formation (see below).
Thrombin can upregulate genes capable of inducing or con-
tributing to oncogenesis and angiogenesis (see below). For exam-
ple, in an analysis of two thrombin-treated murine tumor cell lines 357
	 r e v i e w(B16F10 and UMCL) we have observed that thrombin upregu-
lates several of these genes by 2- to 168-fold: GRO-α (Caunt et 
al., 2006), Twist, metalloproteinase 1 and 2, osteopontin, S100 
calcium-binding proteins, and tetraspanin CD151 (T. Tang and 
S.K., unpublished data). These genes are capable of rendering 
tumor cells more virulent and/or metastatic following transfec-
tion. Indeed, Twist has recently been shown to be responsible for 
mammary tumor metastasis as opposed to growth (Yang et al., 
2004). Specific breast gene signatures have been shown to have 
a propensity for metastasis (Minn et al., 2005). It is suggested that 
events similar to these could be enhanced by thrombin.
Thrombin may also be contributing to the malignant phe-
notype by affecting other essential alterations in cell physiology 
heretofore undescribed, such as self-sufficiency in growth sig-
nals, insensitivity to antigrowth signals, resistance to apoptosis, 
and unlimited replication potential, as well as already documented 
sustained angiogenesis and tissue invasion and metastasis.
These events are summarized in Figure 1.
Angiogenesis
The requirement of angiogenesis for tumor growth and metastasis 
is well recognized. Recent studies have revealed that thrombin 
has a significant stimulatory effect on angiogenesis in that it can 
induce vascular growth factors, VEGF-A in tumor cells (Huang et 
al., 2000; Ollivier et al., 2000), or receptor VEGFR2 (Tsopanoglou 
and Maragoudakis, 1999) and Angiopoietin-2 (ANG-2) in endo-
thelial cells (Huang et al., 2002). Thrombin can also stimulate the 
release of VEGF-A (Mohle et al., 1997) and ANG-1 from platelets 
(Li et al., 2001) as well as induce tube formation of endothelial 
cells in a matrigel membrane system (Haralabopoulos et al., 
1997). Direct application of as little as 0.05–0.1 U/ml of thrombin 
to a chorioallantoic chick membrane induces angiogenesis 2- to 
3-fold over a 72 hr period (Figure 2). This is associated with the 
upregulation of VEGF-A and ANG-2 and is blocked with hirudin 
(thrombin inhibitor), as well as a soluble decoy, VEGF-A recep-
Figure 2. Neoangiogenesis in the chorioallantoic membrane
Ten-day-old chick embryos were prepared with filter disks and treated with 
either Pbs, thrombin, thrombin and hirudin, or PAr-1 receptor against TrAP 
at 24 and 48 hr. Neoangiogenesis was evaluated at 72 hr. Adapted from 
caunt et al. (2003).358 tor inhibitor (VEGFR2-Fc), and Angiopoietin receptor inhibitor 
(Tie2-Fc). It is initiated by PAR-1-specific peptide (TRAP) and 
requires activation of protein kinase C, MAP kinase, and PI3 
kinase (Caunt et al., 2003). Recent studies reveal that thrombin 
upregulates and enhances secretion of the angiogenesis and 
tumor-promoting chemokine GRO-α in human MCF7 breast and 
PC3 prostate tumor cells 25- to 64-fold and is also upregulated 
in human umbilical vein (HUVEC) endothelial cells as well as 
human brain microendothelial cells. This upregulation is pivotal in 
thrombin-induced angiogenesis, since thrombin-induced upregu-
lation of angiogenesis, angiogenesis growth factors VEGF, KDR, 
ANG-2, MMP-1, MMP-2, HUVEC tube formation, and cell growth 
is inhibited by anti-GRO-α Ab, or siRNA knockdown of tumor 
as well as HUVEC cell GRO-α. There is recent evidence that 
the tissue factor VIIa complex not only induces the production of 
thrombin, but also activates angiogenesis by cleaving (activating) 
protease-activated receptor 2 (PAR-2) (in synergy with platelet 
PDGF-BB) (Belting et al., 2004).
Platelets contain both angiogenic (VEGF-A, ANG-1, PDGF, 
bFGF) and antiangiogenic growth factors (thrombospondin, PF-
4, endostatin). However, despite the presence of antiangiogenic 
factors, the overall effect of platelets or their thrombin-induced 
releasate on angiogenesis is stimulatory, suggesting that this 
is the predominant mode (Brill et al., 2004, 2005). In addition, 
there is evidence that platelet agonist ligands may have differ-
ent effects on pro- versus antiangiogenesis. This is supported 
by recent work showing that specific activation of protease-acti-
vated receptors 1 and 4 counter-regulates endostatin and VEGF 
release from platelets when stimulated by their proteolytically 
induced agonists—not thrombin per se (which stimulates both 
receptors). The PAR-4 agonist (ATPGKF) suppresses VEGF-A 
release but enhances endostatin release. The PAR-1 agonist 
(TFLLR) induces VEGF-A release but inhibits endostatin release 
(Ma et al., 2005) (Figure 1).
Effect of endogenous thrombin on tumor growth and metas-
tasis: Critique of previous in vitro and in vivo experiments
Animal studies in which tumor cells are treated with exogenous 
thrombin do not represent the true pathophysiologic situation 
since (1) they give no information on endogenous thrombin pro-
duction/concentration at the tumor host interface; and (2) experi-
mental tail vein tumor pulmonary metastasis is a highly artificial 
situation in which 1 × 105–1 × 106 tumor cells are injected as a 
bolus into the tail vein of a mouse, and primary pulmonary entrap-
ment and tumor nodule appearance are monitored. Spontaneous 
metastasis in the host represents the release of considerably 
fewer cells into the circulation, with an as yet unknown fraction of 
these cells actually implanting and growing.
This criticism prompted a study designed to circumvent these 
objections (Hu et al., 2004). This was accomplished by utiliz-
ing a spontaneously metastasizing murine breast tumor, 4T1. 
Pretreating tumor-implanted mice with hirudin (a highly potent 
thrombin inhibitor, Ki 0.05 pM) inhibited implanted tumor growth 
in mice 4- to 11-fold (again highly artificial). However, it also inhib-
ited seeding into the blood and spontaneous metastasis, and it 
increased mouse survival (Hu et al., 2004). The effect on seeding 
into the blood was dramatic, varying from complete to 15- to 32-
fold protection with two different tumor cell lines. Viable seeding 
into the lung was also measured by culturing surviving tumor cells 
in the lung at 7 days. This was similarly protected 17- to 395-fold. 
The protective effect on pulmonary metastasis was >2.2-fold. All cancer cell November 2006
	 r e v i e wTable 1. cancer survival in cancer patients treated with anticoagulants
study Protocol results
Zacharski et al., 1984; confirmed by lebeau et al., 1994 (277 
patients with heparin); Altinbas et al., 2004 (84 patients with 
lmWH)
randomized, 50 patients with sclc, 
coumadin for 26 weeks
survival, 50 versus 23 weeks, p = 0.018, includes 
12 patients with disseminated disease 
no effect in 381 other non-sclc cancer 
patients
FAmoUs (Fragmin Advanced malignancy outcome study) 
(Kakkar et al., 2004)
randomized, double-blind, 385 
patients with cancer, lmWH versus 
placebo, 1 year
survival at 1, 2, and 3 years, p = 0.19  
subgroup of 102 alive at 17 months: 44 versus 24 
months median survival, p = 0.03 
2 years: 78% versus 55%, p = 0.03 
3 years: 60% versus 35%, p = 0.03
mAlT (malignancy and lmWH Treatment) (Klerk et al., 2005) randomized, double-blind, 302 
patients with cancer, lmWH versus 
placebo, 6 weeks
median survival, 8 versus 6.6 months, hazard 
ratio = 0.75  
subgroup of 164 with ≥6 months life  
expectancy: 15.4 versus 9.4 months, p = 0.01  
12 months survival: 39% versus 27%, p = 0.02  
24 months survival: 21% versus 11%, p = 0.02
cloT (comparison of lmWH versus oral Anticoagulant 
Treatment) (lee et al., 2005)
randomized, 602 patients, cancer 
+ vTe, lmWH versus coumadin, 6 
months
no difference in 12 months survival  
subgroup of 150 without metastasis: 80% versus 
64% survival, p = 0.03 in favor of lmWHfive treated animals were alive at 40 days, whereas all five control 
animals were dead.
The above observations come closer to defining an endog-
enous role for thrombin in the induction of a promalignant pheno-
type but could still be criticized for the requirement of injecting 1 × 
105–1 × 106 tumor cells into the flank of an animal—considerably 
higher than the amount of tumor seeded into the blood from a 
tumor nodule. Studies on the effect of hirudin in mice that develop 
spontaneous tumors with time should circumvent this problem. 
Preliminary studies in such a spontaneous mouse prostate tumor 
model (TRAMP) reveal that hirudin treatment inhibits tumor devel-
opment 4-fold over a 17 week period of observation.
Extrapolating from these murine experimental data, it is like-
ly that low-grade thrombin generation may be harmful to some 
patients with malignancies, because it may predispose to enhanced 
growth and metastatic progression of the lesion. Many tumor cells 
have constitutively active tissue factor on their surface, which can 
activate the coagulation system on the catalytic platelet surface with 
generation of thrombin. Low-grade intravascular coagulation, as 
diagnosed by increased fibrinogen turnover (Yoda and Abe, 1981), 
increased plasma levels of fibrinogen/fibrin-related antigen (Yoda 
and Abe, 1981), and increased plasma levels of fibrinopeptide A 
have been observed in most patients with solid tumors (Rickles 
and Edwards, 1983). One study noted elevated fibrinopeptide 
A levels in 60% of patients at time of disease. Persistent eleva-
tion was associated with a poor prognosis (Rickles and Edwards, 
1983). Thus a “vicious” autocrine cycle is established. It is of inter-
est that tissue factor expression correlates with hematogenous 
metastasis in melanoma cells (Fisher et al., 1995; Mueller et al., 
1992) and is associated with the leading edge of invasive breast 
carcinomas (Contrino et al., 1996). In addition, enzymatically active 
thrombin has been reported to be present on surgically removed 
tumor specimens, including malignant melanoma, by affinity-ligand 
histochemical analysis (Zacharski et al., 1995). Thrombin-recep-
tor (PAR-1) overexpression has been reported in human breast 
metastatic tissue in vivo (Even-Ram et al., 1998).
Clinical studies with anticoagulants
The first convincing randomized study was the pioneering work 
of Zacharski and coworkers (Zacharski et al., 1984), who treated cancer cell November 2006 441 cancer patients with coumadin for 26 weeks. Clinical improve-
ment was noted in a subset of 50 patients with SCLC (small cell 
carcinoma of the lung); survival was prolonged from 23 weeks in 
control patients to 50 weeks in treated patients (p = 0.018). This 
work was confirmed by Lebeau et al. (1994), who used heparin 
instead of warfarin and by Altinbas et al., who used low-molecular 
weight heparin (LMWH) (Altinbas et al., 2004; Table 1).
Recently, Kakkar et al. (2004) reported the first large double-
blind study of 385 patients with cancer, employing LMWH versus 
placebo for 1 year. Although no beneficial effect was noted in all 
patients, a subset of 102 patients alive at 17 months showed a 
significantly improved survival of 44 versus 24 months (p = 0.03), 
which persisted at 3 years (60% versus 35%), p = 0.03. Similar 
results were noted in a second large double-blind study of 302 
patients reported by Klerk et al. (2005), in which patients were 
treated with 6 weeks of LMWH versus placebo. Again the major 
effect noted was in a subgroup of 164 patients with a predicted 6 
months or greater survival. The overall improvement was 15.4 ver-
sus 9.4 months (p = 0.01). A greater effect was noted at 2 years 
(21% versus 11%) (p = 0.02). These two latter studies strongly 
suggested that the initial tumor burden was inversely rate limit-
ing with respect to benefit with LMWH. The choice of anticoagu-
lant—coumadin versus LMWH—was examined in a randomized 
study of 602 cancer patients with venous thrombosis in which 
patients were treated for 6 months with LMWH versus coumadin 
(Lee et al., 2005). Again, although no overall benefit was noted at 
12 months, a subgroup of 150 patients without metastasis had a 
better survival with LMWH compared to coumadin (80% versus 
64%; p = 0.03). The benefit of LMWH versus coumadin could be 
explained on the basis of heparin/LMWH having beneficial effects 
other than that of anticoagulation. Indeed, inhibition of P-selectin 
binding of tumor cells to platelets/endothelial cells by heparin has 
been described (Stevenson et al., 2005). It is also of interest that 
the major effect of LMWH is on Xa, although it does inhibit throm-
bin as well, but to a lesser extent. In addition, hirudin, a specific 
inhibitor of thrombin, is similarly effective, and Xa is required for 
the production of thrombin. However, an independent effect of Xa 
cannot be ruled out. These recent clinical studies demonstrate for 
the first time that the numerous murine studies cited in this review 
may have human relevance.359
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Of particular interest are the observations of Shulman and 
Lindmarker (2000), who followed 854 patients who had been 
treated for 6 months versus 6 weeks with coumadin for deep 
vein thrombosis for the ensuing 6 years. Those patients treated 
for 6 months developed significantly less cancer during the 6 
year observation period than those exposed to anticoagulant for 
6 weeks with an odds ratio of 1.6 (95% CI 1.1–2.4; p = 0.02), and 
when confined to 40 patients with urogenital tumors, the odds 
ratio increased to 2.5 (95% CI 1.3–5.0). It is intriguing to speculate 
that these data, as well as recent animal observations, suggest 
that thrombin may be contributing to preserving tumor dormancy, 
with later growth stimulated by critical concentration of thrombin. 
Other factors, such as immune surveillance and angiogenesis, 
are also likely to play a role. One can further speculate that tumor 
cells lie dormant and/or grow slowly in systemic organs of many 
cancer-prone individuals and that this dormancy is regulated by 
thrombin as well as endogenous anticoagulants (anti-thrombin 
III, protein C, thrombomodulin, α2 macroglobulin, tissue factor 
pathway inhibitor [TFPI]) and other factors. Indeed, it has been 
estimated that it takes 2–8 years for cancer cells to be detectable 
after transformation to malignant cells, considering the doubling 
time and volume required for detection.
What is the evidence for tumor dormancy (Table 2)? It is 
well recognized that many if not all subjects harbor tumor cells 
at various states of dedifferentiation (Table 1). Fatal melanoma 
has been described in two kidney transplant recipients 16 years 
after surgical cure in the donor (MacKie et al., 2003). Autopsies 
of individuals dying from accidents or nonmalignant disease often 
reveal microscopic or in situ cancer. Thyroid cancer is detected in 
38% of 101 consecutive autopsies (Harach et al., 1985). Breast 
cancer is detected in 20% of 110 consecutive autopsies (Nielsen 
et al., 1987). Prostate cancer is detectable in 15%–30% of autop-
sies, with increasing incidence with age (Konety et al., 2005). 
Chronic lymphatic leukemia (CLL) clones are found in “normal” 
elderly men as well as close-degree relatives of patients with 
CLL (Rawstron et al., 2002). Elderly individuals with monoclonal 
nonspecific gammopathy of undetermined significance (MGUS) 
have a 1%/year conversion rate to develop multiple myeloma or 
lymphoma (Kyle, 1997).
It is particularly intriguing to comment on the Second 
Northwick Park Heart Study (Miller et al., 2004), which prospec-
tively studied hypercoagulability once a year for 4 years with 
follow-up of 11 years in a cohort of 3052 middle-aged men, clini-
cally free of malignancy, for the development of myocardial infarc-
Table 2. Tumor dormancy
supporting data reference
Fatal melanoma in two kidney transplant recipients, 
16 years after “surgical cure” in donor; 13 other  
similar reports 6 months–8 years after donor cure
macKie et al., 2003
Thyroid cancer in 36% of 101 consecutive autopsies; 
6%–28% in six other series of 1558 autopsies
Harach et al., 1985
breast cancer in 20% of 101 consecutive autopsies; 
37% at ages 40–54
Nielsen et al., 1987
Prostate cancer in 5%–30% of autopsies, which 
increased with age
Konety et al., 2005
cll clones in “normal” elderly men and close relatives rawstron et al., 2002
elderly individuals with mGUs have a 1%/year  
conversion rate to multiple myeloma or lymphoma
Kyle, 1997360 tion. Hypercoagulability was defined as two yearly consecutive 
positive measurements of both increased prothrombin activation 
fragments 1+2 as well as fibrinopeptide A, exceeding the upper 
quartiles of the population. This was found in 111 men. Although 
no greater incidence of myocardial infarction was noted, total 
mortality from cancer was higher in those with persistent activa-
tion than the other group, 11.3% versus 5.1%, respectively, with 
a relative risk of 2.2 (p = 0.015). This was due largely to higher 
mortality from gastrointestinal cancer, 6.3% versus 1.9%, with a 
relative risk of 3.26 (p < 0.001). This was also associated with an 
earlier diagnosis of gastrointestinal cancer as well as a more rapid 
course to death. This prospective study is remarkably powerful in 
supporting the role of thrombin as a contributing factor to cancer 
development and/or progression.
The experimental animal data, as well as the intriguing 
observation of Shulman and Lindmarker (2000) and the recent 
report of Miller et al. (2004), provide compelling evidence for 
the use of an appropriate anti-thrombin agent for the adjuvant 
treatment of patients with newly diagnosed cancer. The par-
ticular tumor or dosing regimen and duration of therapy remain 
to be determined. But it is likely that this approach would be 
efficacious in patients immediately after the diagnosis of can-
cer, rather than after the tumor burden becomes too great to 
be responsive. A second concern is the deleterious effect of 
anti-thrombotic agents on bleeding, although this was not a 
major complication in the double-blind FAMOUS and MALT 
trials (e.g., 4% versus 2% in control groups). Since the major 
anti-thrombin effect appears to be on its reaction with PAR-1, 
agents that inhibit this reaction may be safer than those inhibit-
ing blood coagulation.
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